We use cookies to improve your browsing experience on our website.
Please visit our Privacy Notice for more information about cookies and how we use them. We recommend that you accept the use of cookies for better navigation.

Newsroom

Show
October 25, 2018
KCI Achieves 10,000-Patient Milestone with iOn PROGRESS™ Remote Therapy Monitoring
Data Demonstrate Proprietary Digital At-Home Monitoring Technology Increases Patient Adherence to NPWT
SAN ANTONIO, October 25, 2018 – Today, KCI, an Acelity Company, announced it has remotely monitored its 10,000th patient through the Company’s iOn PROGRESS™ Remote Therapy Monitoring. Working in conjunction with the ACTIV.A.C.™ Therapy System, iOn PROGRESS™ Remote Therapy Monitoring is the first-to-market system to deliver continuous at-home monitoring for patients prescribed negative pressure wound therapy (NPWT) in the home. It securely transmits data to the KCI iOn PROGRESS™ Care Network, a group of Virtual Therapy Specialists who monitor the data and call patients to drive proper adherence.

A 510-patient retrospective study recently published in WOUNDS found that the day following an adherence call from the iOn PROGRESS™ Care Network, 73.5 percent of patients increased therapy use, with an average increase of 8 hours. Additionally, as adherence increased, patients’ rate of daily change in wound volume reduction increased from 1.42 percent change in volume reduction per day for patients with less than 60 percent therapy use to 2.23 percent change for patients with 90 to 100 percent therapy use.
 
“Our first-to-market connective technology, combined with the patient engagement model we’ve established with our iOn PROGRESS™ Remote Therapy Monitoring, allows us to directly intervene and drive compliance, enhancing our commitment to improving both patient experience and clinical outcomes,” said R. Andrew Eckert, President and CEO of Acelity. “Chronic wounds cost $50 billion annually in the U.S. alone – the data show that this technology can have real impact in addressing that burden and reaching 10,000 patients is a milestone to celebrate the lives we’ve helped restore as we expand our digital health focus at KCI.”

As indicated by a World Health Organization report, adherence amongst patients with a chronic illness is estimated to be only 50%.1 Patient noncompliance with prescribed treatment is a serious problem across many therapeutic areas and permeates into negative pressure wound therapy. iOn PROGRESS™ Remote Therapy Monitoring aims to raise patient compliance, while offering physicians confidence when sending patients home to continue treatment of their wounds. KCI is currently engaged with 35 managed care organizations to provide the technology to their patients.
 
Along with 10,000 patients monitored using iOn PROGRESS™ Remote Therapy Monitoring, KCI has gathered other tangible data since launch in 2017 including more than 300,000 therapy days tracked and more than 30,000 engagement calls made to patients and clinicians from the KCI iOn PROGRESS™ Care Network. 

About iOn PROGRESS™ Remote Therapy Monitoring
iOn PROGRESS™ Remote Therapy Monitoring is the first System to deliver continuous at-home monitoring for patients prescribed NPWT in the home. It works in conjunction with the ACTIV.A.C.™ Therapy System to monitor adherence and securely transmit data to the KCI iOn PROGRESS™ Care Network, a group of highly-trained individuals who interact with patients to drive adherence.
 
About KCI, an Acelity Company
KCI, an Acelity Company, the most trusted brand in advanced wound care, is committed to developing innovative healing solutions for customers and patients across the care continuum. Our unsurpassed product portfolio is available in more than 90 countries and delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Committed to advancing the science of healing, KCI sets the standard for leading advanced wound therapy innovation. Headquartered in San Antonio, Texas, KCI employs nearly 5,000 people around the world.

Ref: 1.chisholm-Burns MA, Spivey CA. The ‘cost’ of medication nonadherence: consequences we cannot afford to accept. J Am Pharm Assoc (2003). 2012;52(6):823–826.

For more information, contact: 

 

Maggie Fairchild

Corporate Communications

Phone: +1-210-330-2667

Email: maggie.fairchild@acelity.com

 

Jathan Tucker,

Investor Relations

Phone: +1-210-255-6817

Email: jathan.tucker@acelity.com